Victoria Helow
Jacksonville, FLNPI 1679682264
Payments from drug & device makers
What this record shows
Merck accounts for 74.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $1,988 and has fallen 85.0% since, to $297 in 2024.
Across 25 payments — averaging $100.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Edwards Lifesciences$283
- AbbVie$237
- Novo Nordisk$87
- Otsuka America Pharmaceutical, Inc.$25
- Exact Sciences$14
Across 80 payments — averaging $9968.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$422K
- Modernatx, Inc.$271K
- Alnylam Pharmaceuticals Inc.$64K
- Astrazeneca UK Limited$41K
- Eli Lilly$290
What the payments were for
- Travel & lodging$1,45958%
- Food & beverage$1,06042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 17 | $1,874 |
| Edwards Lifesciences | 3 | $283 |
| AbbVie | 2 | $237 |
| Novo Nordisk | 1 | $87 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.